A prospective, randomized, open-label, active-controlled, two-arm parallel intervention study in T2DM patients with high cardiovascular risk treated with SGLT2 inhibitors or sulfonylureas for 30 days analyzed the activation of NLRP3 inflammasomes in macrophages. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.